Turnstone Biologics Overview

  • Founded
  • 2015

Founded
  • Status
  • Private

  • Employees
  • 123

Employees
  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $80M

  • Investors
  • 19

Turnstone Biologics General Information

Description

Developer of viral immunotherapies designed for cancer immunotherapies to improve survival. The company's immunotherapies combine a bio-selected and engineered oncologic virus to directly lyse tumors with a potent vaccine technology to drive tumor-antigen-specific T-cell responses, enabling bio-medical professionals to generate immune responses, treat cancer and modulate the tumor environment.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Drug Delivery
Primary Office
  • 9310 Athena Circle
  • Suite 300
  • La Jolla, CA 92037
  • United States
+1 (347) 000-0000

Turnstone Biologics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Turnstone Biologics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series D) 14-Jul-2021 $80M 00000 Completed Pre-Clinical Trials
5. Later Stage VC 19-Dec-2019 00000 00000 Completed Pre-Clinical Trials
4. Later Stage VC (Series C) 04-Jan-2019 0000 000.00 Completed Startup
3. Early Stage VC (Series B) 02-Nov-2016 000.00 000.00 Completed Startup
2. Early Stage VC (Series A) 28-Oct-2015 $11.3M $11.3M Completed Startup
1. Early Stage VC 04-May-2015 Completed Startup
To view Turnstone Biologics’s complete valuation and funding history, request access »

Turnstone Biologics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of viral immunotherapies designed for cancer immunotherapies to improve survival. The company's immunotherapie
Biotechnology
La Jolla, CA
123 As of 2022
00000
00000000000 00000

000000

r sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut lab
0000 000000000
Middleton, WI
00 As of 0000
000.00
0000000000 0 000.00

0000 0

eniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo c
0000 000000000
South San Francisco, CA
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Turnstone Biologics Competitors (54)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Centrose Venture Capital-Backed Middleton, WI 00 000.00 0000000000 0 000.00
0000 000000 Venture Capital-Backed South San Francisco, CA 00 00000 00000000000 00000
000000 Venture Capital-Backed Rochester, MN 00 00000 00000000000 00000
00000000 Venture Capital-Backed Watertown, MA 00 0000 00000000000 0000
000000 000000000 Angel-Backed New York, NY 00000 0000000000 00000
You’re viewing 5 of 54 competitors. Get the full list »

Turnstone Biologics Patents

Turnstone Biologics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3152796-A1 Methods for inducing an immune response against neoantigens Pending 27-Aug-2019 00000000000
EP-4021470-A2 Methods for inducing an immune response against neoantigens Pending 27-Aug-2019 00000000000
US-20220305099-A1 Methods for inducing an immune response against neoantigens Pending 27-Aug-2019 00000000000
JP-2022514420-A Modified orthopox viral vector Pending 21-Dec-2018 00000000000
EP-3898998-A4 Modified orthopoxvirus vectors Pending 21-Dec-2018 C07K16/2818 0
To view Turnstone Biologics’s complete patent history, request access »

Turnstone Biologics Executive Team (16)

Name Title Board Seat Contact Info
Sammy Farah Ph.D Chief Executive Officer, President & Board Member
Venkat Ramanan Ph.D Chief Financial Officer
José Otero Ph.D Chief Technology Officer
Saryah Azmat Chief Business Officer
Mike Burgess Ph.D Interim Chief Medical Officer, Executive Director & Board Member
You’re viewing 5 of 16 executive team members. Get the full list »

Turnstone Biologics Board Members (12)

Name Representing Role Since
Ben Auspitz F-Prime Capital Board Member 000 0000
Bradley Bolzon Ph.D Versant Ventures Board Member 000 0000
Jerel Davis Ph.D Versant Ventures Chairman 000 0000
Kanya Rajangam Ph.D Self Board Member 000 0000
Mike Burgess Ph.D Turnstone Biologics Interim Chief Medical Officer, Executive Director & Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Turnstone Biologics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Turnstone Biologics Investors (19)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
CaaS Capital Management Hedge Fund Minority 000 0000 000000 0
Eventide Asset Management Asset Manager Minority 000 0000 000000 0
JM Family Enterprises Corporation Minority 000 0000 000000 0
Northleaf Capital Partners Limited Partner Minority 000 0000 000000 0
PFM Health Sciences Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 19 investors. Get the full list »

Turnstone Biologics Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000 00000000 20-Jan-2021 0000000000 Biotechnology 00000 000
To view Turnstone Biologics’s complete acquisitions history, request access »